Protect Life's Moments
With GAMMAGARD LIQUID
[Immune Globulin Infusion (Human)]10%
Demonstrated tolerability across
two routes of administration for PI patients1
GAMMAGARD LIQUID offers two routes of administration for your patients - intravenous (IV) and subcutaneous (SC). Find out more about each, and about which might be the right decision for your patient.
WARNING: THROMBOSIS, RENAL DYSFUNCTION and ACUTE RENAL FAILURE
- Thrombosis may occur with immune globulin products, including GAMMAGARD LIQUID. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
- Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients with immune globulin intravenous (IGIV) products including GAMMAGARD LIQUID. Renal dysfunction and acute failure occur more commonly with IGIV products containing sucrose. GAMMAGARD LIQUID does not contain sucrose.
- For patients at risk of thrombosis, administer GAMMAGARD LIQUID at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.
Reference: 1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [Prescribing Information]. Westlake Village, CA: Baxalta US Inc.
GAMMAGARD LIQUID IVFind out more about GAMMAGARD LIQUID IV administration.
GAMMAGARD LIQUID SCLearn about SC administration of GAMMAGARD LIQUID.
More info Dosing GAMMAGARD LIQUID SubQ CoPay Card
IV or SC?See the differences between IV and SC administration.
GAMMAGARD S/D (IV only)GAMMAGARD S/D IgA less than 1 ɥg/mL in a 5% solution for patients who require a low-IgA IV treatment. Find out more
Clinical QuestionsFind answers to common clinical questions. Get answers